Metaraminol en es it fr

Metaraminol Brand names, Metaraminol Analogs

Metaraminol Brand Names Mixture

  • No information avaliable

Metaraminol Chemical_Formula


Metaraminol RX_link

Metaraminol fda sheet

Metaraminol msds (material safety sheet)

Metaraminol MSDS

Metaraminol Synthesis Reference

Brit. pat. 353,361 (1930 to I. G. Farben); Brit. pat. 396,951 (1932 to I. G. Farben); Swiss pat. 162,267 (1931 to I. G. Farben); U.S. pats. 1,948,162 ans 1,951,302; Hartung, U.S. pat. 1,995,709 (1935 to Sharp & Dohme)

Metaraminol Molecular Weight

167.205 g/mol

Metaraminol Melting Point

107.5 oC

Metaraminol H2O Solubility

1000 g/L

Metaraminol State


Metaraminol LogP


Metaraminol Dosage Forms

Intramuscular injection; Intravenous injection

Metaraminol Indication

For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage

Metaraminol Pharmacology

Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol acts on both α1-adrenergic receptors but appears to have no effect on β-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.

Metaraminol Absorption

The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection.

Metaraminol side effects and Toxicity

LD50=240 mg/kg (rat, oral); LD50=99 mg/kg (mouse, oral)

Metaraminol Patient Information

Metaraminol Organisms Affected

Humans and other mammals